Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- A QMS That Anticipates Cell And Gene Therapy Quality Challenges
- Using Digital Platforms To Find Your CDMO
- July 2026 — CDMO Opportunities And Threats Report
- ADC CDMO Selection For Small Biotech
- Implementing AI Solutions In GMP While Managing Risk
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- Europe's ATMP Opportunity Still Requires Local Navigation
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Sensitive RNA Fluorescent Quantitation With An RNA Assay Kit
Accurate nucleic acid quantification is vital for applications like PCR and NGS. Discover an RNA Assay Kit that offers precise RNA measurement to enhance reliability and performance in downstream assays.
-
Overcoming Analytical Bottlenecks In Oligonucleotide Drug Development With Automation
Growing oligonucleotide complexity is straining traditional analytical workflows. See how automated LC‑UV‑MS processing offers a scalable way to boost throughput and reduce manual effort.
-
Multi-Column Chromatography For Efficient Polishing Purification
Boost downstream efficiency with multi-column chromatography for polishing to achieve higher productivity, reduced resin costs, and automated operation while maintaining purity and recovery.
-
Meeting Annex 1: A Proactive Approach To Regulatory Compliance
It was imperative for a large European CMO producing multiple biologics to select the right product quality and value for each customer to comply with the August 2023 EU GMP Annex 1 revision.
-
Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids
3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.
-
Efficient Clone Screening With Increased Process Control And Integrated Cell Health And Titer Measurements With The Cydem VT Automated Clone Screening System
Automated screening of antibody-producing clones provides real-time cell health and titer data, helping developers identify top-performing candidates earlier and with confidence.
-
Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
Studying The Spatial Architecture Of Glioblastoma
Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).
-
Addressing A Critical Drug Shortage
A critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.
-
Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility
Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.
NEWSLETTER ARCHIVE
- 09.04.26 -- New Podcast Episodes: Fixing AAV Recovery, Cell Therapy Advances, Reimagining Solid Tumor Immunotherapy
- 09.04.26 -- The Blueprint For Viral Vector Manufacturing Success
- 09.04.26 -- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- 09.03.26 -- Real-Time Visibility Is Reshaping Outsourced Gene Therapy
- 09.03.26 -- How To Match CGT Manufacturing Models To Pipeline Needs With Legend Biotech
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections